思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT
Phase III Study Results of Envafolimab Plus GEMOX in First-Line Treatment of Advanced Biliary Tract Cancer to be Officially Presented at 2026 ASCO Annual Meeting

This announcement is made by 3D Medicines Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board of Directors (the "**Board**") of the Company is pleased to announce that the key findings from the Phase III pivotal clinical trial of 恩維達® (Envafolimab Injection), the Company's innovative immuno-oncology drug, have been successfully selected for official presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As the world's first commercially launched subcutaneous PD-L1 inhibitor and the first single-domain antibody for tumor treatment globally, 恩維達® is co-developed by the Company and Alphamab Oncology (9966.HK). It features convenient administration and excellent safety profiles. Having been approved and marketed in China for four years, the product has achieved cumulative sales of over RMB2 billion in China. The Group is currently in active negotiations for the rights of 恩維達® in the United States, Japan and Europe. Advanced biliary tract cancer is characterized by poor prognosis and limited clinical treatment options, leaving a huge unmet clinical need. The release of the Phase III study data will further validate the clinical value of 恩維達® in the field of hepatobiliary tumors and expand its indication coverage and commercial sales in the Chinese market. The study is a prospective, randomized, active-controlled, open-label, national multi-center Phase III pivotal trial focusing on the first-line treatment of Chinese patients with advanced biliary tract cancer. It aims to evaluate the efficacy and safety of 恩維達® plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone. As the world's first large-scale registrational clinical trial evaluating the combination regimen of the first subcutaneously administered PD-L1 monoclonal antibody plus GEMOX as first-line therapy for biliary tract cancer (BTC), this study has yielded favorable survival benefits. It directly provides high-level evidence-based medical data for China's clinical practice guidelines, helps optimize the strategies for immune combination therapy of BTC in China, and carries significant scientific implications and clinical value.

Key Presentation Information:

Abstract Publication Number: 4118
Presentation Session: Gastrointestinal, Pancreatic and Hepatobiliary Cancer
Poster Board: 101
Presentation Time: 9:00 AM – 12:00 PM CDT, May 30, 2026

In addition, three other clinical studies of the Group have also been accepted for presentation at the 2026 ASCO Annual Meeting.

This announcement only discloses phased academic achievements. The approval of new indications is subject to subsequent data verification and regulatory review with inherent uncertainties. Shareholders and potential investors are advised to exercise caution when making investment decisions.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, May 27, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.